PMID- 30095603
OWN - NLM
STAT- MEDLINE
DCOM- 20191021
LR  - 20191022
IS  - 1536-481X (Electronic)
IS  - 1057-0829 (Linking)
VI  - 27
IP  - 10
DP  - 2018 Oct
TI  - Prospective Evaluation of XEN Gel Implant in Eyes With Pseudoexfoliative 
      Glaucoma.
PG  - 869-873
LID - 10.1097/IJG.0000000000001045 [doi]
AB  - PURPOSE: The main purpose of this study was to compare the safety and efficacy of 
      XEN gel implant surgery in patients with pseudoexfoliative glaucoma (PEXG) and 
      primary open-angle glaucoma (POAG). SETTING: This was a prospective, 
      interventional study in a tertiary glaucoma center. METHODS: Fifty-seven eyes (43 
      patients) with POAG and 53 eyes (42 patients) with PEXG with uncontrolled 
      intraocular pressure (IOP) despite medical treatment underwent combined 
      XEN+cataract surgery or standalone XEN surgery. Mean IOP, mean number of 
      medications at 1-year follow-up, needling rates, and incidence of adverse effects 
      (AEs) were analyzed. Complete success, defined as an IOP <16 mm Hg without 
      medications at 1 year, was also analyzed. RESULTS: Combined XEN+cataract surgery 
      was performed in 72% of POAG and 75% of PEXG eyes (P=0.674), the remainder 
      underwent standalone XEN surgery. Patient characteristics were similar between 
      the 2 groups except for higher age for the PEXG patients (78.5+/-8.5 vs. 71.3+/- 8.7 
      y; P<0.001). Mean medicated IOP was 19.8+/-5.8 (POAG) and 19.7+/-8.2 (PEXG) at 
      baseline (P=0.98) and 13.9+/-4.6 (-29.8%) and 13.6+/-4.3 mm Hg (-31%) at 1 year 
      (P=0.87), respectively (P<0.01). Mean medications dropped from 1.9+/-1.6 (POAG) and 
      2.0+/-1.3 (PEXG) preoperatively to 0.4+/-0.8 and 0.5+/-0.8, respectively at 1 year 
      (P<0.001). A total of 42% (POAG) and 63% (PEXG) eyes achieved complete success 
      (P=0.06) at 1 year. Needling was performed in 36.8% (POAG) versus 37.7% (PEXG) 
      (P=0.923). CONCLUSIONS: The XEN gel implant as a standalone or combined procedure 
      demonstrated similar efficacy and safety results in PEXG and POAG eyes.
FAU - Mansouri, Kaweh
AU  - Mansouri K
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Vision Network, Lausanne, 
      Switzerland.
AD  - Department of Ophthalmology, University of Colorado School of Medicine, Denver, 
      CO.
FAU - Gillmann, Kevin
AU  - Gillmann K
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Vision Network, Lausanne, 
      Switzerland.
FAU - Rao, Harsha L
AU  - Rao HL
AD  - Narayana Nethralaya, Hulimavu, Bengaluru, Karnataka, India.
FAU - Guidotti, Jacopo
AU  - Guidotti J
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Vision Network, Lausanne, 
      Switzerland.
FAU - Mermoud, Andre
AU  - Mermoud A
AD  - Glaucoma Research Center, Montchoisi Clinic, Swiss Vision Network, Lausanne, 
      Switzerland.
LA  - eng
SI  - ClinicalTrials.gov/NCT03151577
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - J Glaucoma
JT  - Journal of glaucoma
JID - 9300903
RN  - 0 (Gels)
SB  - IM
MH  - Aged
MH  - Aged, 80 and over
MH  - Exfoliation Syndrome/*surgery
MH  - Female
MH  - *Gels
MH  - *Glaucoma Drainage Implants
MH  - Glaucoma, Open-Angle/*surgery
MH  - Humans
MH  - Intraocular Pressure/physiology
MH  - Male
MH  - Middle Aged
MH  - Phacoemulsification/*methods
MH  - Prospective Studies
MH  - Tonometry, Ocular
EDAT- 2018/08/11 06:00
MHDA- 2019/10/23 06:00
CRDT- 2018/08/11 06:00
PHST- 2018/08/11 06:00 [pubmed]
PHST- 2019/10/23 06:00 [medline]
PHST- 2018/08/11 06:00 [entrez]
AID - 10.1097/IJG.0000000000001045 [doi]
PST - ppublish
SO  - J Glaucoma. 2018 Oct;27(10):869-873. doi: 10.1097/IJG.0000000000001045.